A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study

Investigational New Drugs

Volumn 23, Issue 5, 2005, Pages 485-487

  Macdonald, John S ^a   McCoy, Sheryl ^b   Whitehead, Robert P ^c   Iqbal, Syma ^d   Wade III, James L ^e   Giguere, Jeffrey K ^f   Abbruzzese, James L ^g  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Central Illinois Community Clinical Oncology Program   (United States)

^f Greenville Community Clinical Oncology Program   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Clinical trial; Farnesyl; Pancreas; Transferase

Indexed keywords

BILIRUBIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ABDOMINAL CRAMP; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPHYXIA; ASPIRATION PNEUMONIA; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONVALESCENCE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HEALTH STATUS; HUMAN; HYPOKALEMIA; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LETHARGY; LEUKOPENIA; LIVER FUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; ONCOLOGY; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SOMNOLENCE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT FAILURE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; FARNESYLTRANSTRANSFERASE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PANCREATIC NEOPLASMS; QUINOLONES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 23844517889     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-2908-y     Document Type: Article

References (8)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002.
2. Schnall, SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-228, 1996.
3. Yeo CJ, Cameron JL, Sohn TA: Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226: 248-257, 1997.
4. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson F, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
5. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61: 131-137, 2001.
6. Grünewald K, Lyons J, Fröhlich A: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43: 1037-1041, 1989.
7. Cohen SJ, Linus H, Sulabha R, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21(7): 1301-1306, 2003.
8. Van Custem E, Karasek P, Oettle H, Vervenne W, Szawlowski A, Schoffski P, Post S, Neumann H, Safran H, Humblet Y, van de Velde H, Ma Y, Von Hoffl: Phase III trial comparing gemcitabine +R11577 (Zarnestra) versus gemcitabine +placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21: 130a, 2002 (abstr 21).